- Ongoing, recruitingTherapeutic exploratory (Phase II)
Proof of concept study to assess the efficacy and safety of Danicopan (factor D inhibitor) in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment (DANICSU).
This study looks at a new medicine called Danicopan for adults with long-lasting hives (urticaria) that haven't gotten better with standard allergy pills. It aims to see if Danicopan is safe and helps reduce hives, especially for those with different allergy levels.
For: Chronic spontaneous urticariaGermany - Active not recruitingPHASE3
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
This study looks at the long-term safety and effectiveness of a drug called Danicopan. It's for people with a rare blood condition called PNH who are already taking another PNH medicine, a C5 inhibitor. Danicopan is given as an add-on treatment.
For: Paroxysmal Nocturnal HemoglobinuriaUnited States · Brazil · Canada - RecruitingPHASE3
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
This study looks at a new add-on medicine, danicopan, for young people (12-17 years old) with a rare blood condition called PNH. It aims to see if danicopan can improve red blood cell levels when added to their current treatment.
For: Paroxysmal Nocturnal Hemoglobinuria · PNH · Extravascular HemolysisCanada · France · United Kingdom